Market Performance of Aquestive Therapeutics (AQST)
Current Trading Activity
AQST traded up 1.32 % during a 24‑hour period ending at 05:19 PM Central Europe on Tuesday, 20 October 2026.
The share price is approximately USD 4.08 on major exchanges.
Market Capitalisation and Volume
Shares outstanding: 125.5 million.
Market capitalisation: USD 474.4 million.
Trading volume in the last 24 hours: USD 12.8 million.
The stock has declined 19.87 % since the previous month‑end.
Technical Indicators
200‑day simple moving average: USD 4.26.
52‑week high: USD 7.18 (recorded 24 October 2025).
52‑week low: USD 2.93 (recorded 30 January 2026).
Corporate Governance Update
On 19 October 2026, Aquestive Therapeutics filed an 8‑K report detailing changes to its governance structure:
- Adoption of amended and restated bylaws, effective 15 October 2026.
- Modifications to provisions regarding stockholder nominations and the definition of “Stockholder Associated Person.”
- Streamlining of the nomination process by removing certain relationship disclosures previously required.
- Confirmation of a change in the fiscal year‑end.
- The filing includes financial statements and related exhibits.
- No additional business developments or regulatory actions were disclosed.
Comparative Stock Activity (Last 24 Hours)
| Symbol | Company | % Change | Current Price (USD) | Market Cap (USD mn) | PE Ratio (where applicable) |
|---|---|---|---|---|---|
| KRNY | Kearny /Md | –1.11 % | 9.07 | 561.3 | 15.57 |
| EVEX | Eve | –0.62 % | 1.68 | 564.6 | – |
| CRMD | Cormedix | +1.65 % | 7.52 | 565.9 | 3.52 |
| CLYM | Climb Bio | –0.92 % | 10.74 | 564.0 | – |
| SGMT | Sagimet Biosciences | +10.47 % | 9.88 | 568.7 | – |
Cormedix Update
- The U.S. Food and Drug Administration accepted the supplemental New Drug Application for REZZAYO® (once‑weekly antifungal) under priority review.
- The application, submitted by global development partner Mundipharma, targets prevention of invasive fungal disease in patients undergoing allogeneic stem‑cell transplantation.
- Positive results from the Phase III ReSPECT study support the application.
- FDA target action date: first quarter of 2027.
- Upon approval, CorMedix plans promotional activities in the second half of 2027.
Company Profile
- Name: Aquestive Therapeutics, Inc.
- Industry: Pharmaceutical / Health Care.
- Location: Warren, United States.
- Product Focus: Medicines and therapeutic solutions for central nervous system diseases; late‑stage proprietary pipelines.
- Market: Exclusive service to customers within the United States.
- Website: www.aquestive.com
- Public Listing: Nasdaq, since 25 July 2018.
